202 related articles for article (PubMed ID: 34731787)
21. Azacitidine Use for Myeloid Neoplasms.
El Fakih R; Komrokji R; Shaheen M; Almohareb F; Rasheed W; Hassanein M
Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):e147-e155. PubMed ID: 29478947
[TBL] [Abstract][Full Text] [Related]
22. Azacitidine access program for Belgian patients with myelodysplastic syndromes, acute myeloid leukemia or chronic myelomonocytic leukemia.
Meers S; Selleslag D; Potier H; Glasmacher A; Mineur P; Voelter V
Curr Med Res Opin; 2015 Jan; 31(1):35-42. PubMed ID: 25317956
[TBL] [Abstract][Full Text] [Related]
23. Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia.
Helbig G; Chromik K; Woźniczka K; Kopińska AJ; Boral K; Dworaczek M; Koclęga A; Armatys A; Panz-Klapuch M; Markiewicz M
Pathol Oncol Res; 2019 Jul; 25(3):1175-1180. PubMed ID: 30613922
[TBL] [Abstract][Full Text] [Related]
24. Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.
Seymour JF; Döhner H; Butrym A; Wierzbowska A; Selleslag D; Jang JH; Kumar R; Cavenagh J; Schuh AC; Candoni A; Récher C; Sandhu I; Del Castillo TB; Al-Ali HK; Falantes J; Stone RM; Minden MD; Weaver J; Songer S; Beach CL; Dombret H
BMC Cancer; 2017 Dec; 17(1):852. PubMed ID: 29241450
[TBL] [Abstract][Full Text] [Related]
25. Azacitidine for Relapse After Allogeneic Stem Cell Transplantation-Single-Center Study.
Karakulska-Prystupiuk E; Drozd-Sokołowska J; Waszczuk-Gajda A; Stefaniak A; Dwilewicz-Trojaczek J; Kulikowska A; Chmarzyńska-Mróz E; Basak G; Paluszewska M; Boguradzki P; Jędrzejczak W
Transplant Proc; 2018 Sep; 50(7):2212-2217. PubMed ID: 30177138
[TBL] [Abstract][Full Text] [Related]
26. Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine.
Breccia M; Fianchi L; Lunghi M; Gaidano G; Levis A; Finelli C; Santini V; Musto P; Mansueto G; Oliva EN; Leoni P; Spiriti MA; Hohaus S; Leone G; Alimena G; Voso MT
Leuk Lymphoma; 2013 Aug; 54(8):1786-7. PubMed ID: 23151268
[No Abstract] [Full Text] [Related]
27. Patterns of infection in patients with myelodysplastic syndromes and acute myeloid leukemia receiving azacitidine as salvage therapy. Implications for primary antifungal prophylaxis.
Falantes JF; Calderón C; Márquez-Malaver FJ; Aguilar-Guisado M; Martín-Peña A; Martino ML; Montero I; González J; Parody R; Pérez-Simón JA; Espigado I
Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):80-6. PubMed ID: 24220615
[TBL] [Abstract][Full Text] [Related]
28. Response to treatment with azacitidine in children with advanced myelodysplastic syndrome prior to hematopoietic stem cell transplantation.
Waespe N; Van Den Akker M; Klaassen RJ; Lieberman L; Irwin MS; Ali SS; Abdelhaleem M; Zlateska B; Liebman M; Cada M; Schechter T; Dror Y
Haematologica; 2016 Dec; 101(12):1508-1515. PubMed ID: 27540140
[TBL] [Abstract][Full Text] [Related]
29. Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia.
Voso MT; Niscola P; Piciocchi A; Fianchi L; Maurillo L; Musto P; Pagano L; Mansueto G; Criscuolo M; Aloe-Spiriti MA; Buccisano F; Venditti A; Tendas A; Piccioni AL; Zini G; Latagliata R; Filardi N; Fragasso A; Fenu S; Breccia M;
Eur J Haematol; 2016 Apr; 96(4):344-51. PubMed ID: 26018238
[TBL] [Abstract][Full Text] [Related]
30. Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival.
Cabezón M; Malinverni R; Bargay J; Xicoy B; Marcé S; Garrido A; Tormo M; Arenillas L; Coll R; Borras J; Jiménez MJ; Hoyos M; Valcárcel D; Escoda L; Vall-Llovera F; Garcia A; Font LL; Rámila E; Buschbeck M; Zamora L;
Clin Epigenetics; 2021 Jan; 13(1):9. PubMed ID: 33446256
[TBL] [Abstract][Full Text] [Related]
31. Proposed diagnostic criteria and classification of basophilic leukemias and related disorders.
Valent P; Sotlar K; Blatt K; Hartmann K; Reiter A; Sadovnik I; Sperr WR; Bettelheim P; Akin C; Bauer K; George TI; Hadzijusufovic E; Wolf D; Gotlib J; Mahon FX; Metcalfe DD; Horny HP; Arock M
Leukemia; 2017 Apr; 31(4):788-797. PubMed ID: 28090091
[TBL] [Abstract][Full Text] [Related]
32. Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia.
Winters AC; Maloney KW; Treece AL; Gore L; Franklin AK
Pediatr Blood Cancer; 2020 Oct; 67(10):e28398. PubMed ID: 32735397
[TBL] [Abstract][Full Text] [Related]
33. Azacitidine: a review of its use in higher-risk myelodysplastic syndromes/acute myeloid leukaemia.
Keating GM
Drugs; 2009; 69(17):2501-18. PubMed ID: 19911860
[TBL] [Abstract][Full Text] [Related]
34. Enumeration and immunohistochemical characterisation of bone marrow basophils in myeloproliferative disorders using the basophil specific monoclonal antibody 2D7.
Agis H; Krauth MT; Mosberger I; Müllauer L; Simonitsch-Klupp I; Schwartz LB; Printz D; Böhm A; Fritsch G; Horny HP; Valent P
J Clin Pathol; 2006 Apr; 59(4):396-402. PubMed ID: 16461568
[TBL] [Abstract][Full Text] [Related]
35. The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine.
Miltiades P; Lamprianidou E; Vassilakopoulos TP; Papageorgiou SG; Galanopoulos AG; Kontos CK; Adamopoulos PG; Nakou E; Vakalopoulou S; Garypidou V; Papaioannou M; Hatjiharissi E; Papadaki HA; Spanoudakis E; Pappa V; Scorilas A; Tsatalas C; Kotsianidis I;
Clin Cancer Res; 2016 Apr; 22(8):1958-68. PubMed ID: 26700206
[TBL] [Abstract][Full Text] [Related]
36. Mutational analysis in serial marrow samples during azacitidine treatment in patients with post-transplant relapse of acute myeloid leukemia or myelodysplastic syndromes.
Woo J; Howard NP; Storer BE; Fang M; Yeung CC; Scott BL; Deeg HJ
Haematologica; 2017 Jun; 102(6):e216-e218. PubMed ID: 28209655
[No Abstract] [Full Text] [Related]
37. Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry.
Bernal T; Martínez-Camblor P; Sánchez-García J; de Paz R; Luño E; Nomdedeu B; Ardanaz MT; Pedro C; Amigo ML; Xicoy B; del Cañizo C; Tormo M; Bargay J; Valcárcel D; Brunet S; Benlloch L; Sanz G; ; ;
Leukemia; 2015 Sep; 29(9):1875-81. PubMed ID: 25943181
[TBL] [Abstract][Full Text] [Related]
38. The euphoria of hypomethylating agents in MDS and AML: is it justified?
Sekeres MA
Best Pract Res Clin Haematol; 2013 Sep; 26(3):275-8. PubMed ID: 24309530
[TBL] [Abstract][Full Text] [Related]
39. Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study.
Prebet T; Sun Z; Ketterling RP; Zeidan A; Greenberg P; Herman J; Juckett M; Smith MR; Malick L; Paietta E; Czader M; Figueroa M; Gabrilove J; Erba HP; Tallman MS; Litzow M; Gore SD;
Br J Haematol; 2016 Feb; 172(3):384-91. PubMed ID: 26577691
[TBL] [Abstract][Full Text] [Related]
40. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.
Garcia-Manero G; Gore SD; Cogle C; Ward R; Shi T; Macbeth KJ; Laille E; Giordano H; Sakoian S; Jabbour E; Kantarjian H; Skikne B
J Clin Oncol; 2011 Jun; 29(18):2521-7. PubMed ID: 21576646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
